# Bidirectional ventricular tachycardia due to digoxin-diuretic interaction in post-cardiac surgery patient: a case report

**Authors:** José Martín Alanís-Naranjo, Kevin David Aragón-Ontiveros, Julio César Rivera-Hermosillo, Virginia Campos-Garcilazo

PMC · DOI: 10.47487/apcyccv.v5i2.362 · 2024-06-24

## TL;DR

A 62-year-old woman developed a rare heart rhythm disorder after cardiac surgery, linked to digoxin and diuretic use, highlighting the need for careful monitoring.

## Contribution

This case report highlights digoxin-induced bidirectional ventricular tachycardia in post-cardiac surgery patients on diuretics, a rare and under-recognized clinical scenario.

## Key findings

- The patient developed hemodynamically stable bidirectional ventricular tachycardia due to digoxin toxicity.
- Supportive treatment with potassium and magnesium supplements was effective when digoxin-specific antibodies were unavailable.
- The case emphasizes the importance of monitoring digoxin levels in patients on concurrent diuretic therapy.

## Abstract

Bidirectional ventricular tachycardia (BVT) is a rare form of malignant ventricular arrhythmia characterized by beat-to-beat alternation in the QRS axis. BVT is a hallmark of digitalis toxicity, but digoxin-induced BVT secondary to digoxin-diuretic interaction in cardiac surgery patients is not widely reported. We present the case of a 62-year-old woman undergoing mitral valve replacement with tricuspid annuloplasty who developed postoperative congestive heart failure and vasoplegic syndrome requiring norepinephrine, vasopressin, and loop diuretics. During postoperative care, she presented atrial fibrillation with rapid ventricular response, achieving rate control with digoxin, but later displayed hemodynamically stable BVT associated with digitalis toxicity. The case highlights the importance of physicians monitoring digoxin toxicity when prescribing digoxin to patients with a diuretic regimen, particularly loop diuretics. During digoxin-induced-BVT, supportive treatment, including discontinuing digitalis coupled with potassium and magnesium supplements, can be considered as long as digoxin-specific antibodies are unavailable, and the patient is hemodynamically stable.

## Linked entities

- **Chemicals:** digoxin (PubChem CID 2724385), norepinephrine (PubChem CID 951), vasopressin (PubChem CID 8230), potassium (PubChem CID 813), magnesium (PubChem CID 5462224)
- **Diseases:** congestive heart failure (MONDO:0005009), bidirectional ventricular tachycardia (MONDO:0022568), atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Diseases:** vasoplegic syndrome (MESH:D056987), atrial fibrillation (MESH:D001281), toxicity (MESH:D064420), congestive heart failure (MESH:D006333), ventricular arrhythmia (MESH:D001145), BVT (MESH:C535438)
- **Chemicals:** potassium (MESH:D011188), digitalis toxicity (-), magnesium (MESH:D008274), norepinephrine (MESH:D009638), digoxin (MESH:D004077)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11247964/full.md

---
Source: https://tomesphere.com/paper/PMC11247964